A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Enliven Therapeutics
The purpose of this study is to test the safety and early signs of efficacy of an experimental drug called ELVN-002 for the treatment of solid tumors carrying HER2 genetic alterations, in particular NSCLC and breast cancer.
Enrollment Form
This study is currently enrolling.